Trial Profile
A Phase 1 Study of Concurrent Cabozantinib and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Cetuximab (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 02 Dec 2022 Status changed from recruiting to active, no longer recruiting.
- 18 Apr 2022 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.